AVIR Stock Price, Atea Pharmaceuticals Inc Quote, Chart

Market Summary

USD3.66-0.04

Delayed

-1.08%

AVIR Stock Price

View Fullscreen

AVIR RSI Chart

AVIR Valuation

Market Cap

308.3M

Price/Earnings (Trailing)

-1.88

Price/Sales (Trailing)

14.3

EV/EBITDA

-0.91

Price/Free Cashflow

-3.23

AVIR Price/Sales (Trailing)

AVIR Profitability

EBT Margin

-754.55%

Return on Equity

-32.45%

Return on Assets

-29.59%

Free Cashflow Yield

-30.95%

AVIR Fundamentals

AVIR Revenue

Revenue (TTM)

21.6M

Rev. Growth (Yr)

9.03%

Rev. Growth (Qtr)

-5.96%

AVIR Earnings

Earnings (TTM)

-163.7M

Earnings Growth (Yr)

-78.11%

Earnings Growth (Qtr)

-61.29%

Breaking Down AVIR Revenue

Last 7 days

-5.9%

Last 30 days

-1.3%

Last 90 days

-11.2%

Trailing 12 Months

2.0%

How does AVIR drawdown profile look like?

AVIR Financial Health

Current Ratio

13.28

AVIR Investor Care

Shares Dilution (1Y)

0.99%

Diluted EPS (TTM)

-1.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	21.6M	0	0	0
2023	153.5M	87.5M	0	0
2022	285.4M	219.4M	0	0
2021	124.3M	200.0M	275.7M	351.4M
2020	0	0	0	48.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Atea Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 01, 2024	hammond janet mj	sold	-53,913	3.843	-14,029	chief development officer
Feb 01, 2024	vavricka john	sold	-45,420	3.843	-11,819	chief commercial officer
Feb 01, 2024	horga maria arantxa	sold	-60,963	3.8414	-15,870	chief medical officer
Feb 01, 2024	foster wayne	sold	-47,904	3.8394	-12,477	evp, chief accounting officer
Feb 01, 2024	corcoran andrea	sold	-60,914	3.8449	-15,843	see remarks
Feb 01, 2024	sommadossi jean-pierre	sold	-218,819	3.845	-56,910	president, ceo, and chairman
Jan 31, 2024	hammond janet mj	acquired	-	-	46,800	chief development officer
Jan 31, 2024	vavricka john	acquired	-	-	33,334	chief commercial officer
Jan 31, 2024	horga maria arantxa	acquired	-	-	41,534	chief medical officer
Jan 31, 2024	foster wayne	acquired	-	-	33,334	evp, chief accounting officer

Which funds bought or sold AVIR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Tidal Investments LLC	new	-	86,747	86,747	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-43.42	-60,188	179,978	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-7,349	31,136	-%
May 15, 2024	HSBC HOLDINGS PLC	reduced	-4.99	138,588	692,327	-%
May 15, 2024	Point72 (DIFC) Ltd	new	-	25,169	25,169	-%
May 15, 2024	LM Advisors LLC	sold off	-100	-153	-	-%
May 15, 2024	BARCLAYS PLC	reduced	-26.16	-13,000	588,000	-%
May 15, 2024	AMERIPRISE FINANCIAL INC	added	97.83	264,363	427,505	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	21.69	103,000	272,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-72.48	-472,411	270,947	-%

Are Funds Buying or Selling AVIR?

Are funds buying AVIR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVIR

No. of Funds

Unveiling Atea Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ecor1 capital, llc	8.4%	6,995,861	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	8.4%	6,995,861	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	8.4%	6,995,861	SC 13G/A
Feb 13, 2024	sommadossi jean-pierre	7.1%	5,925,000	SC 13G/A
Feb 13, 2024	vanguard group inc	5.51%	4,599,710	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	bml investment partners, l.p.	6.7%	5,462,079	SC 13G
Feb 07, 2024	bml investment partners, l.p.	6.7%	5,462,079	SC 13G/A
Jan 24, 2024	blackrock inc.	11.3%	9,443,887	SC 13G/A
Nov 28, 2023	tang capital partners lp	4.8%	4,033,463	SC 13D/A

Recent SEC filings of Atea Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Feb 28, 2024	8-K	Current Report
Feb 28, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Atea Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Atea Pharmaceuticals Inc News

Latest updates

Atea Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q2	2023Q1	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-6.0%	7.00	7.00	6.00	1.00	97.00	192	33.00	60.00	66.00	-
Operating Expenses	98.1%	70.00	35.00	42.00	32.00	42.00	71.00	55.00	52.00	35.00	28.00
S&GA Expenses	-100.0%	-	13.00	13.00	12.00	13.00	13.00	12.00	12.00	9.00	14.00
R&D Expenses	161.0%	58.00	22.00	29.00	20.00	30.00	58.00	43.00	40.00	27.00	14.00
EBITDA Margin	-504.3%	-7.53*	-1.25*	-0.73*	0.12*	0.23*	0.39*	0.14*	0.21*	0.19*	-
Income Taxes	-8.0%	0.00	0.00	0.00	0.00	-	-	6.00	7.00	-	-
Earnings Before Taxes	-125.3%	-62.94	-27.93	-35.27	-31.21	-42.08	121	-22.09	9.00	31.00	21.00
EBT Margin	-503.5%	-7.55*	-1.25*	-0.73*	0.12*	0.23*	0.39*	0.14*	0.21*	0.19*	-
Net Income	-124.1%	-63.17	-28.18	-35.47	-31.33	-42.08	117	-28.19	2.00	31.00	21.00
Net Income Margin	-526.1%	-7.59*	-1.21*	-0.71*	0.07*	0.17*	0.34*	0.09*	0.18*	0.19*	-
Free Cashflow	-147.3%	-39.86	-16.12	-29.85	-21.06	-59.05	-75.43	23.00	-17.35	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-7.0%	553	595	608	626	638	667	687	694	717	773	844	872	841	864	110	-
Current Assets	-7.1%	549	590	603	621	632	661	682	689	713	772	843	871	840	863	108	22.00
Cash Equivalents	11.9%	161	144	138	214	183	188	176	684	706	765	840	816	834	850	105	22.00
Net PPE	-8.1%	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	22.3%	49.00	40.00	26.00	24.00	20.00	26.00	23.00	34.00	37.00	63.00	262	274	254	316	-	-
Current Liabilities	27.6%	41.00	32.00	19.00	16.00	12.00	18.00	16.00	25.00	29.00	57.00	262	274	254	316	11.00	2.00
Shareholder's Equity	-9.2%	504	555	582	602	618	641	663	660	680	710	581	598	586	548	-	-
Retained Earnings	-32.3%	-259	-195	-156	-123	-95.35	-59.88	-25.45	-17.38	14.00	56.00	-61.10	-32.91	-34.45	-65.16	-85.82	-54.21
Additional Paid-In Capital	1.7%	763	751	739	726	714	701	689	678	666	654	642	631	621	613	9.00	5.00
Shares Outstanding	0.9%	84.00	83.00	83.00	83.00	83.00	83.00	83.00	83.00	83.00	83.00	83.00	83.00	-	-	-	-
Float	-	-	-	-	284	-	-	-	537	-	-	-	1,615,148	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-82.6%	-39,865	-21,834	-17,591	-16,120	-29,850	-21,545	-21,242	-19,186	-59,009	-75,423	22,603	-17,348	-16,837	318,521	-9,481	-7,798	-4,508	-	-	-
Share Based Compensation	3.5%	12,586	12,157	12,383	12,353	12,535	11,645	11,504	11,908	11,661	11,351	10,990	10,007	7,273	2,821	4,238	209	189	-	-	-
Cashflow From Investing	104.5%	56,802	27,771	-58,513	46,565	24,480	33,488	-486,975	-1,879	-44.00	-	-	-	-	-5.00	-15.00	-	-	-	-	-
Cashflow From Financing	-	150	-	92.00	-	165	-	147	-	223	142	795	57.00	471	426,218	-913	106,449	-6.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AVIR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 57,575	$ 28,954
General and administrative	12,231	12,615
Total operating expenses	69,806	41,569
Loss from operations	(69,806)	(41,569)
Interest income and other, net	6,868	6,299
Loss before income taxes	(62,938)	(35,270)
Income tax expense	(231)	(197)
Net loss	(63,169)	(35,467)
Other comprehensive loss
Unrealized gain (loss) on available-for-sale investments	(388)	377
Comprehensive loss	$ (63,557)	$ (35,090)
Net loss per share - basic and diluted
Basic	$ (0.75)	$ (0.43)
Diluted	$ (0.75)	$ (0.43)
Weighted-average number of common shares - basic and diluted
Basic	83,916,193	83,332,397
Diluted	83,916,193	83,332,397

AVIR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 160,910	$ 143,823
Marketable securities	380,581	434,283
Prepaid expenses and other current assets	7,273	12,349
Total current assets	548,764	590,455
Property and equipment, net	1,185	1,289
Other assets	1,396	1,396
Operating lease right-of-use assets, net	1,684	1,828
Total assets	553,029	594,968
Current liabilities
Accounts payable	21,137	4,252
Accrued expenses and other current liabilities	19,405	27,364
Current portion of operating lease liabilities	769	760
Total current liabilities	41,311	32,376
Operating lease liabilities	1,445	1,642
Income taxes payable	5,902	5,758
Total liabilities	48,658	39,776
Commitments and contingencies (see Note 12)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 300,000,000 shares authorized; 84,223,100 and 83,435,513 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	84	83
Additional paid-in capital	763,472	750,737
Accumulated other comprehensive gain (loss)	(181)	207
Accumulated deficit	(259,004)	(195,835)
Total stockholders’ equity	504,371	555,192
Total liabilities and stockholders’ equity	$ 553,029	$ 594,968

About Atea Pharmaceuticals Inc

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

CEO	Dr. Jean-Pierre Sommadossi Ph.D.
WEBSITE	https://ateapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	72

Atea Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Atea Pharmaceuticals Inc? What does AVIR stand for in stocks?

AVIR is the stock ticker symbol of Atea Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atea Pharmaceuticals Inc (AVIR)?

As of Fri May 17 2024, market cap of Atea Pharmaceuticals Inc is 308.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVIR stock?

You can check AVIR's fair value in chart for subscribers.

What is the fair value of AVIR stock?

You can check AVIR's fair value in chart for subscribers. The fair value of Atea Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Atea Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVIR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Atea Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AVIR is over valued or under valued. Whether Atea Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Atea Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVIR.

What is Atea Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AVIR's PE ratio (Price to Earnings) is -1.88 and Price to Sales (PS) ratio is 14.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVIR PE ratio will change depending on the future growth rate expectations of investors.